Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA act mut |
Therapy | STX-478 |
Indication/Tumor Type | Her2-receptor negative breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA act mut | Her2-receptor negative breast cancer | predicted - sensitive | STX-478 | Phase Ib/II | Actionable | In a Phase I/II trial, STX-478 treatment was well tolerated and resulted in a response rate of 21% in heavily pre-treated patients with advanced solid tumors harboring mutations in PIK3CA (n=43), with a response rate of 23% (5/22) in patients with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (Ann Oncol (2024) 35 (suppl_2): S1220; NCT05768139). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients | Full reference... |